Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer.

Trial Profile

Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Samarium-153-SM-lexidronam (Primary) ; Calcium; Strontium-89; Vitamin D analogues; Zoledronic acid
  • Indications Advanced breast cancer; Bone metastases; Lung cancer; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jan 2011 Last checked against University of Southern California Norris Comprehensive Cancer Center record.
    • 30 Jun 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top